Rose Weldon - Cullinan Oncology Senior Communications
| CGEM Stock | USD 12.22 0.36 2.86% |
Executive
Rose Weldon is Senior Communications of Cullinan Oncology LLC
| Address | One Main Street, Cambridge, MA, United States, 02142 |
| Phone | 617 410 4650 |
| Web | https://cullinantherapeutics.com |
Cullinan Oncology Management Efficiency
The company has return on total asset (ROA) of (0.204) % which means that it has lost $0.204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2653) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.4. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 13.8 M, while Non Current Assets Total are likely to drop about 3.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Robert Richard | Lyra Therapeutics | 66 | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Ronan JD | Lyra Therapeutics | 51 | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Scott Saywell | Coherus BioSciences | N/A | |
| David MS | Ikena Oncology | N/A | |
| PharmD BCOP | Bolt Biotherapeutics | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Bob Lally | Ikena Oncology | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Michael Chen | Coherus BioSciences | N/A | |
| Jami Taylor | Coherus BioSciences | N/A | |
| Alexander Constan | Ikena Oncology | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.2 |
Cullinan Oncology LLC Leadership Team
Elected by the shareholders, the Cullinan Oncology's board of directors comprises two types of representatives: Cullinan Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cullinan. The board's role is to monitor Cullinan Oncology's management team and ensure that shareholders' interests are well served. Cullinan Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cullinan Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Michaelson, Chief Officer | ||
| Kerry Whalen, Director Devel | ||
| Jeffrey Trigilio, CFO Treasurer | ||
| Mary Fenton, Chief Officer | ||
| Jacquelyn JD, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Patrick Baeuerle, Chief CoFounder | ||
| Steve Andre, Chief Officer | ||
| Kevin Johnston, Chief Officer | ||
| Corinne Savill, Chief Officer | ||
| Mary CPA, Chief Officer | ||
| Nadim Ahmed, CEO President | ||
| Rose Weldon, Senior Communications |
Cullinan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cullinan Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 135.91 M | ||||
| Shares Outstanding | 58.23 M | ||||
| Shares Owned By Insiders | 4.49 % | ||||
| Shares Owned By Institutions | 95.51 % | ||||
| Number Of Shares Shorted | 9.02 M | ||||
| Price To Earning | 5.23 X | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 26.88 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.